| Literature DB >> 29263657 |
Shingo Noguchi1, Kazuhiro Yatera1, Tatsuji Kato2, Yasuo Chojin2, Yoshihisa Fujino3, Kentaro Akata1, Toshinori Kawanami1, Noriho Sakamoto4, Hiroshi Mukae4.
Abstract
INTRODUCTION: The clinical significance of the number of aspiration risk factors in patients with pneumonia is unknown as yet. In the present study, we clarify the significance of the number of aspiration risk factors for mortality and recurrence in pneumonia patients.Entities:
Keywords: aspiration pneumonia; bedridden; dementia; mortality; recurrence of pneumonia; sleeping medications
Mesh:
Substances:
Year: 2017 PMID: 29263657 PMCID: PMC5724415 DOI: 10.2147/CIA.S150499
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Entry flow chart.
Characteristics of 322 patients with pneumonia
| Characteristics | Patients with pneumonia |
|---|---|
| Age (years), mean ± SD | 83.4±12.2 |
| Female; n (%) | 187 (58.1) |
| ECOG-PS 4; n (%) | 105 (32.6) |
| Hospitalization for ≥2 days in the preceding 90 days; n (%) | 80 (24.8) |
| Comorbidity; n (%) | |
| Malignancy | 73 (22.7) |
| Chronic cerebrovascular disease | 186 (57.8) |
| Chronic cardiovascular disease | 182 (56.5) |
| Chronic respiratory disease | 124 (38.5) |
| Gastroesophageal disease | 57 (17.7) |
| Chronic liver disease | 18 (5.6) |
| Chronic kidney disease | 14 (4.3) |
| Diabetes mellitus | 47 (14.6) |
| Dementia | 240 (74.5) |
| Orientation disturbance; n (%) | 11 (3.4) |
| Albumin <3.0 g/dL; n (%) | 106 (32.9) |
| Radiographic findings; n (%) | |
| Multilobar involvement (≥2) | 107 (33.2) |
| Pleural effusion | 87 (27.0) |
| Sleeping medications | 63 (19.6) |
| Tube feeding | 21 (6.5) |
| ACE inhibitor drugs | 19 (5.9) |
| PSI score; n (%) | |
| I–III | 63 (19.6) |
| IV | 143 (44.4) |
| V | 116 (36.0) |
| 30 days mortality | 25 (7.8) |
| Recurrence of pneumonia within | 95 (31.4) |
| 30 days | |
| 6-month mortality | 63 (23.2) |
Notes:
ECOG-PS4 cannot move at all or perform personal care, all day spent in bed or chair.
Recurrence of pneumonia was evaluated in 303 patients.
6-month mortality was evaluated in 271 patients.
Abbreviations: ACE, angiotensin-converting enzyme; ECOG-PS, European Cooperative Oncology Group-performance status; PSI, pneumonia severity index.
The number of aspiration risk factors in each category
| Characteristics | Risk 0–1 | Risk 2 | Risk 3 | Risk ≥4 |
|---|---|---|---|---|
| Age (years), mean ± SD | 75.8±16.7 | 86.6±8.6 | 86.7±7.7 | 85.8±6.9 |
| Female; n (%) | 48 (51.6) | 67 (59.8) | 56 (63.6) | 16 (55.2) |
| Hospitalization for ≥2 days in the preceding 90 days; n (%) | 16 (17.2) | 30 (26.8) | 23 (26.1) | 11 (37.9) |
| Comorbidity; n (%) | ||||
| Malignancy | 19 (20.4) | 23 (20.5) | 23 (26.1) | 8 (27.6) |
| Chronic cardiovascular disease | 40 (43.0) | 68 (60.7) | 58 (65.9) | 16 (55.2) |
| Chronic respiratory disease | 35 (37.6) | 50 (44.6) | 26 (29.5) | 13 (44.8) |
| Chronic liver disease | 5 (5.4) | 4 (3.6) | 7 (8.0) | 2 (6.9) |
| Chronic kidney disease | 1 (1.1) | 5 (4.5) | 4 (4.5) | 4 (13.8) |
| Diabetes mellitus | 14 (15.1) | 14 (12.5) | 10 (11.4) | 9 (31.0) |
| Albumin <3.0 g/dL | 19 (20.4) | 35 (31.3) | 38 (43.2) | 14 (48.3) |
| Radiographic findings; n (%) | ||||
| Multilobar involvement (≥2) | 32 (34.4) | 36 (32.1) | 30 (34.1) | 9 (31.0) |
| Pleural effusion | 16 (17.2) | 28 (25.0) | 31 (35.2) | 12 (41.4) |
| Tracheotomy | 0 (0.0) | 0 (0.0) | 1 (1.1) | 1 (3.4) |
| Tube feeding | 2 (2.2) | 4 (3.6) | 10 (11.4) | 5 (17.2) |
| ACE inhibitor drugs | 3 (3.2) | 6 (5.4) | 6 (6.8) | 4 (13.8) |
| PSI score; n (%) | ||||
| I–III | 42 (45.2) | 15 (13.4) | 5 (5.7) | 1 (3.4) |
| IV | 34 (36.6) | 55 (49.1) | 43 (48.9) | 11 (37.9) |
| V | 17 (18.3) | 42 (37.5) | 40 (45.5) | 17 (58.6) |
| Aspiration risk factors in this study; n (%) | ||||
| Orientation disturbance | 2 (2.2) | 5 (4.5) | 1 (1.1) | 3 (10.3) |
| ECOG-PS4 | 1 (1.1) | 19 (17.0) | 58 (65.9) | 27 (93.1) |
| Chronic cerebrovascular disease | 12 (12.9) | 68 (60.7) | 78 (88.6) | 28 (96.6) |
| Dementia | 28 (30.1) | 98 (87.5) | 85 (96.6) | 29 (100.0) |
| Sleeping medications | 5 (5.4) | 20 (17.9) | 23 (26.1) | 15 (51.7) |
| Gastroesophageal disease | 9 (9.7) | 14 (12.5) | 19 (21.6) | 15 (51.7) |
Note:
ECOG-PS4 cannot move at all or perform personal care, all day spent in bed or chair.
Abbreviations: ACE, angiotensin-converting enzyme; ECOG-PS, European Cooperative Oncology Group-performance status; PSI, pneumonia severity index.
Figure 2The ratio of each outcome and odds ratio according to the number of aspiration risk factors.
Note: (A) Recurrence of pneumonia within 30 days, (B) 30-day mortality, (C) 6-month mortality.
Abbreviations: OR, odds ratio; Ref, reference.
Figure 3The ratio for each outcome according to the aspiration risk.
Notes: (A) Recurrence of pneumonia within 30 days. (B) The receiver operating characteristics for recurrence of pneumonia. (C) 30-day mortality. (D) The receiver operating characteristics for 30-day mortality. (E) 6-month mortality. (F) The receiver operating characteristics for 6-month mortality.
Abbreviations: AUC, areas under the curve; NS, not significant.
The evaluation of 6 risk factors using multivariate analysis
| Variables | Multivariate analysis
| ||
|---|---|---|---|
| Odds ratio | 95% CI | ||
| Orientation disturbance | 0.52 | 0.10–2.62 | 0.425 |
| Chronic cerebrovascular disease | 1.51 | 0.86–2.68 | 0.153 |
| Dementia | 5.26 | 2.30–12.03 | <0.001 |
| ECOG-PS 4 | 3.31 | 1.83–6.00 | <0.001 |
| Sleeping medications | 2.08 | 1.04–4.14 | 0.038 |
| Gastroesophageal disease | 1.15 | 0.56–2.35 | 0.709 |
Abbreviation: ECOG-PS, European Cooperative Oncology Group-performance status.